Arrowhead Pharmaceuticals Inc develops medicines using its targeted RNAi molecule, TRiM, platform that uses a natural pathway to silence genes causing disease. It has commercialized Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS). Redemplo has received marketing authorization for FCS across the European Union, the USA, Canada, Australia, China, and the United Kingdom. Additionally, the company has several drug candidates in clinical trials ranging from early to late stage, including both partnered and wholly-owned candidates such as Zodasiran, Olpasiran, Fazirsiran, ARO-C3, and others being developed as therapies for various cardiometabolic, pulmonary, liver, neuromuscular, and other conditions.
Last trade$43.02
Day change-$1.195 (-2.70%)
Day range$42.15 – $46.07
Volume1,333,166
Market cap$6.25B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.25B
Price / earnings
—
Price / book
124.22×
Price / sales
13.86×
EV / sales
15.67×
EV / EBITDA
-10.38×
Profitability
Earnings per share
-$5.12
Return on assets
-41.66%
Return on equity
-1,439.39%
Dividend yield
0%
Liquidity and leverage
Debt / equity
17.47×
Current ratio
4.14×
Quick ratio
4.11×
Cash ratio
0.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$283.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARWR, quarterly periods
Line item
Q4 FY2026 Sep 30, 2026
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Revenue
$37.79M
$75.25M
$73.74M
$264.03M
$256.47M
$27.77M
$542.71M
$2.5M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$37.79M
$75.25M
$73.74M
$264.03M
$256.47M
$27.77M
$542.71M
$2.5M
Selling, general and administrative
$68.96M
$47.12M
$41.74M
$46.02M
$37.68M
$30.95M
$28.41M
$26.91M
Research and development
$190.47M
$198.22M
$173.25M
$177.2M
$174.69M
$162.37M
$133.1M
$137M
Total operating expenses
$474.42M
$245.35M
$215M
$223.22M
$212.37M
$193.32M
$161.51M
$163.91M
Operating income
-$436.63M
-$170.09M
-$141.26M
$40.81M
$44.11M
-$165.55M
$381.2M
-$161.41M
Interest expense
-$22.8M
-$24.56M
-$23.85M
-$22.51M
-$21.69M
-$24.38M
-$21.64M
-$21.65M
Income before taxes
-$435.71M
-$178.91M
-$137.57M
$28.27M
$36.12M
-$179.09M
$369.62M
-$175.12M
Income taxes
-$6.83M
$11K
$7K
$29K
$20M
-$437K
$1.75M
$103K
Net income
-$428.89M
-$178.92M
-$137.57M
$28.24M
$16.12M
-$178.65M
$367.86M
-$175.22M
Net income attributable to common shareholders
-$428M
-$194.28M
-$132.73M
$30.81M
-$23.75M
-$175.24M
$370.45M
-$173.09M
EBITDA
-$429.42M
-$163.43M
-$134.89M
$47.2M
$50.49M
-$159.33M
$387.29M
-$156.18M
Basic earnings per share
-$2.98
-$1.36
-$0.93
$0.22
-$0.17
-$1.26
$2.78
-$1.39
Diluted earnings per share
-$3.06
-$1.36
-$0.93
$0.22
-$0.17
-$1.26
$2.75
-$1.39
Recent news
Company coverage with links to the original publishers.
The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.
The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.
The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.
The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.
CRISPR Therapeutics reported strong Q4 2025 results with Casgevy gene therapy generating $116 million in annual revenue and 147 patient initiations, nearly tripling from 2024. The company is advancing its pipeline with in vivo liver editing programs and RNA-based candidates. Shares surged 8.81% on the positive clinical progress and expanding market access.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.